PHAR3717

This course is designed to increase the learner’s understanding of the complex relationship between Type 2 diabetes, insulin resistance, and metabolic syndrome. Students will explore the pharmacotherapy of Type 2 diabetes, including the pathophysiology, non-drug treatment measures, and the most common drug therapy available for treatment, including oral medications, insulin, and Glucagon-like peptide-1 receptor agonists (GLP-1s). It is nearly impossible to discuss these topics without also discussing body weight, weight loss, and the weight stigma prevalent in both our society and healthcare system. The course will describe the function of adipocytes as endocrine cells and the complex system of appetite regulation, and explore how medications used to treat Type 2 diabetes also impact body weight and health outcomes. You will discuss how issues such as drug shortages, drug pricing, and drug policy and regulation impact patient access to medications, especially insulin and GLP-1s. The course will explore the role of weight inclusive care in this complex environment, and provide students the opportunity to evaluate sources of information and engage in personal reflection to increase self-awareness.

Every Fall